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In the last few years, the cancer field has
gained greater insights into and
increased appreciation for the genes and
pathways involved in the maintenance of
genome integrity. Indeed, it has long
been recognized that most, if not all,
human cancers display aberrations in
chromosome count and structure whose
recurrent nature belies a pathogenetic
link to cancer development (Lengauer et
al., 1998). For certain human cancers,
such as those of the hematopoeitic sys-
tem, there exists ample genetic evidence
that certain recurrent chromosomal
translocations are diagnostic and
causative (Rowley, 2001). While debate
continues over the origins of such
changes and their precise contributions
to carcinogenesis (Marx, 2002), mount-
ing experimental evidence has strength-
ened the view that periods of genetic
instability can propel aspiring cancer
cells toward a lethal malignant endpoint.
The path to our current understand-
ing has been illuminated largely through
the systematic analysis of mouse models
defective for telomere maintenance, DNA
repair, and tumor suppressor pathway
function (Hakem and Mak, 2001; Maser
and DePinho, 2002). These model sys-
tems have demonstrated that mice, defi-
cient in the various “caretakers” of the
genome, sustain a spectrum of tumors
that recapitulate more closely certain
cytogenetic aspects of human cancers.
Particularly informative have been mouse
models harboring deficiencies of compo-
nents of the nonhomologous end-joining
pathway (NHEJ) of DNA double-strand
break (DSB) repair (Ferguson and Alt,
2001). Unable to complete the pro-
grammed rearrangements initiated by
DSBs induced by the RAG-1/2 nuclease,
these mutant mouse strains have offered
a novel view of the potential conse-
quences of a free DSB—namely, the
checkpoints elicited by unrepaired DSBs
and the detrimental impact of inappropri-
ate DSB repair. Mice deficient for p53
checkpoint function alone sustain high
rates of T cell lymphomas and sarcomas,
yet remarkably these tumors lack charac-
teristic chromosome structural anomalies
and exhibit only modest levels of aneu-
ploidy. In contrast, mice with dual impair-
ments in NHEJ and p53 function
succumb to highly aggressive pro-B cell
lymphomas possessing signature
chromosomal rearrangements whose
anatomy points to a defective V(D)J
recombination process (Difilippantonio et
al., 2002; Gladdy et al., 2003 [this issue
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The analysis of compound mouse mutants for nonhomologous end-joining DNA double-strand break repair and those defi-
cient for the p53 checkpoint pathway has provided a fascinating look at the carcinogenic consequences of the failure to
properly repair DNA damage and to elicit appropriate checkpoints.
Figure 1. Creating a cancerous genome in
the absence of NHEJ and p53, and path-
ways to pro-B cell lymphoma in mice
A: In cells lacking p53 checkpoint function,
the failure of NHEJ to properly repair the DNA
DSB created by RAG-induced cleavage at
IgH leads to the formation of aberrant chro-
mosomes (translocations and dicentrics). In
turn, these can result in c-myc amplification,
BFB cycles, and further genomic instability,
creating the genetic recipe for pro-B cell
lymphoma in mice.
B: Once initiated, improper completion of
V(D)J recombination in mice lacking NHEJ
and p53 function results in a path that leads
to pro-B cell lymphoma. Alternatively, in the
proper genetic context, generalized
genomic instability in NHEJ-p53 double
mutants may also lead to a path to pro-B cell
lymphoma.
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of Cancer Cell];Vanasse et al., 1999; Zhu
et al., 2002).
These compound NHEJ p53 mutant
model systems have offered a penetrat-
ing view of the cytogenetic and onco-
genic consequences of an introduced
DNA DSB (created by RAG nuclease)
and its aberrant repair in a setting of
attenuated DNA damage checkpoints.
Among these studies, several common
themes have emerged. In each case, for
mice lacking p53 and either Ku70 or
Ku80 (Difilippantonio et al., 2002),
XRCC4 or LIG4 (Zhu et al., 2002), or
carrying a hypomorphic DNA-PKcs
“SCID” mutation (DNA-PKSCID) (Gladdy
et al., 2003; Vanasse et al., 1999), there
emerges lymphomas bearing clonal and
recurrent chromosomal rearrangements.
The advent of high-resolution cytogenet-
ic technologies, such as spectral kary-
otyping and array-comparative genomic
hybridization, has allowed the field to
molecularly define these rearrange-
ments and thereby infer the mechanism
of repair that produced them, gaining
insight into the molecular forces guiding
cancer cell evolution. In nearly every
lymphoma, rearrangements appear to
initiate from the site of RAG-induced
cleavage in the immunoglobulin heavy
chain locus (IgH) on chromosome 12,
and subsequently involved the c-myc
locus on chromosome 15 (Figure 1A).
Repair of the RAG-induced DSB and
generation of the (12;15) translocation
appear to have resulted from a type of
end repair utilizing short homologies
(Difilippantonio et al., 2002; Gladdy et
al., 2003; Zhu et al., 2002). In addition,
evidence suggests that dicentric forma-
tion and ensuing bridge-fusion-breakage
(BFB) cycles are involved in creating an
amplified c-myc locus and more complex
chromosomal rearrangements (Figure
1A) (Difilippantonio et al., 2002; Gladdy
et al., 2003; Zhu et al., 2002).The reason
that c-myc is so frequently involved is
unclear, but may reflect the presence of
fragile sites, cryptic sequences recog-
nized by RAG-1/2, and/or the chance
occurrence of a DSB generated by the
breakage of dicentrics.With regard to the
latter, it is interesting to note that certain
NHEJ deficiencies are associated with
decreased telomere capping function
and the production of telomeric end-to-
end fusions (Bailey et al., 1999; d’Adda
di Fagagna et al., 2001) that would in
turn set the stage for BFB-induced DSBs
throughout the genome. In this scenario,
the critical role of c-Myc dysfunction in
lymphomagenesis would presumably
lead to the selection of rare cells in the
population that harbor an amplified c-
myc locus. Combined, these results point
to the central importance of DSBs in
genomic instability, particularly aberra-
tions in chromosome structure, which
can fuel pro-B cell lymphomagenesis.
More recent work has taken a step
further by assessing the role of RAG in
initiating the DSBs and specific chromo-
some abnormalities that drive pro-B cell
tumors (Difilippantonio et al., 2002;
Gladdy et al., 2003;Vanasse et al., 1999;
Zhu et al., 2002), and unexpectedly,
some different outcomes were observed.
The absence of RAG-1/2 prevents the
initiation of V(D)J recombination due to
the failure to create the initial cleavage at
immune loci; hence, the lack of RAG-1/2
might be expected to prevent pro-B cell
lymphomas in mice deficient for both
NHEJ and p53 function. This was tested
previously (Difilippantonio et al., 2002;
Vanasse et al., 1999; Zhu et al., 2002)
and in the study in this issue of Cancer
Cell (Gladdy et al., 2003) by breeding
RAG-2 deficiency into the various
NHEJ/p53 mutant strains. Not surpris-
ingly, pro-B cell lymphomas with the
recurrent (t12;15) translocations were
suppressed; however, beyond this com-
mon finding, interesting differences were
obtained among the various studies.
Mice mutant for Xrcc4-p53 combined
with RAG-2 deficiency died young,
before they would be expected to devel-
op the p53-associated T cell lymphoma
observed in NHEJ-proficient mice (Zhu
et al., 2002), whereas Ku80-p53 mutant
mice with RAG-2 deficiency did develop
T cell lymphomas at a later age, as do
their Ku80 wild-type p53-deficient coun-
terparts (Difilippantonio et al., 2002).
Vanasse et al. (1999) observed that
DNA-PKSCID-p53-RAG-2 mutant mice
behaved similarly, developing late T cell
rather than early B cell lymphomas.
Whereas this apparent difference in can-
cer phenotype may reflect the shorter
lifespan of the triple mutant Xrcc4-p53-
RAG-2 mice compared to the DNA-
PKSCID-p53-RAG-2 mutant mice, we are
tempted to speculate that this distinction
could reflect in part the differential
impact of the various NHEJ deficiencies
on telomere maintenance (d’Adda di
Fagagna et al., 2001). In striking con-
trast, Gladdy et al. (2003) observed no
reduction in either incidence or latency of
pro-B cell lymphomas in their DNA-
PKSCID-p53-RAG-2 mutant mice com-
pared to DNA-PKSCID-p53 mutant con-
trols. Whereas lymphomas of the DNA-
PKSCID-p53 mutant cohort harbored the
characteristic RAG-induced rearrange-
ments, this tumor was suppressed in the
triple mutant background. In its absence,
however, a different type of pro-B cell
lymphoma was revealed which lacked
the (t12;15) translocation, possessed dif-
ferent translocations, and had different
biological properties. In the latter con-
text, the Gladdy et al. DNA-PKSCID-p53-
RAG-2 mutant pro-B cell lymphomas
were unique in their capacity to spread to
the meninges—the membranes envelop-
ing the central nervous system (Gladdy
et al., 2003). This interesting and novel
experimental outcome suggests that
generalized genomic instability associat-
ed with NHEJ deficiency in the appropri-
ate context can cooperate with p53
checkpoint deficiency to create lesions
capable of endowing pro-B cell lym-
phomas with the capacity to invade and
reside in the meningial membranes—
although, as discussed below, additional
factors may be operative. Nonetheless,
expression of c-Myc was elevated com-
pared to normal lymphoid cells, pointing
to its central importance in lymphoma
pathogenesis and the capacity of c-Myc
to be dysregulated via multiple
mechanisms.
What are we to make of the differ-
ences in the pro-B cell tumor phenotype
arising in the Gladdy et al. triple mutant
DNA-PKSCID-p53-RAG-2 cohort com-
pared to the other studies? As far as can
be discerned, the mutant alleles
employed were identical: RAG-2, DNA-
PKcs (SCID), and p53 (regardless, two
different alleles of p53 have been shown
to behave similarly [Difilippantonio et al.,
2002]). Is it possible that the phenotypic
differences relate to various modifiers
present in these heavily mixed genetic
strains? The fact that NHEJ and p53 defi-
ciencies result in a near-universal pro-B
cell lymphoma condition suggests that
these combined mutations drive this
tumor type regardless of genetic back-
ground in RAG-proficient animals. In the
Gladdy et al. study (Gladdy et al., 2003),
one might assume that a modifier differ-
ence may influence the phenotypic out-
come of the triple mutant mice, although
this seems unlikely given the heavily
mixed composition of the large experi-
mental cohorts examined. Nonetheless,
a specific genetic modifier in the Gladdy
et al. triple mutant cohort cannot be dis-
counted, nor can we exclude the modu-
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lating effects of environmental and
dietary factors. Despite these differ-
ences, it appears that DSBs, whether
induced by the RAG nuclease or by the
random BFB process enabled by
NHEJ/p53 deficiency, can lead to pro-B
cell lymphomas (Figure 1B). These unre-
solved issues should motivate efforts to
identify the genetic and epigenetic fac-
tors that endow lymphoma cells with the
capacity to hone to meningial mem-
branes—an occurrence that is not
uncommon in the lymphoma clinic.
Are there any unifying themes asso-
ciated with these studies? For one, it is
clear that NHEJ deficiency (as well as
other DNA repair defects) results in
genomic instability that can provoke car-
cinogenesis. This becomes abundantly
clear when programmed DNA DSBs are
initiated in the absence of NHEJ in the
lymphoid compartment. Although the c-
myc rearrangements found in the
NHEJ/p53 double mutant murine tumors
are not identical to those typically found
in human cancers (Rowley, 2001), they
are informative nonetheless with respect
to identifying mechanisms that con-
tribute to the chromosomal aberrations
encountered in a wide variety of human
lymphoid and solid tumors. Gene amplifi-
cation (and deletion) can contribute to a
wide spectrum of tumor types, and the
genetic experiments described here and
previous cell culture studies (Pipiras et
al., 1998) indicate that DSBs are crucial
initiators of these events. Second, the
p53 checkpoint mechanism in response
to aberrant DNA DSBs has once again
shown its central importance and an
additional basis for why its loss of func-
tion can participate in the development
of so many tumor types. In the lymphoid
compartment, its function is to force
aberrant cells into apoptosis, rather than
to allow alternative pathways of DNA
repair (Figure 1B). The link between
DSBs, p53 status, dicentric formation,
and increased cancer—particularly
epithelial cancers—was first forged in
mice deficient for telomere function
(Artandi et al., 2000; Chin et al., 1999), in
which p53 loss provides a permissive
context for the increased formation of
chromosomal fusions and recurrent
rearrangements via BFB cycles that fuel
cancer initiation. Analogously, in the
NHEJ mutants, p53′s absence enables
existing DNA damage to be replicated
and create the aberrant chromosomes
found in tumors. Lastly, this body of work
continues to validate the use of geneti-
cally engineered mice as models to
elucidate mechanisms governing chro-
mosome stability and to uncover novel
genetic pathways that promote or pre-
vent human cancer.
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